FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A

The US Food and Drug Administration has granted approval to Fayuvi, known generically as rebisufligene etisparvovec-hopf. The decision marks the first authorized treatment for mucopolysaccharidosis type IIIA, or Sanfilippo syndrome type A. The pediatric condition is a fatal lysosomal storage disorder caused by mutations in the SGSH gene, leading to severe behavioral regression, loss of speech, and rapid neurodegeneration in early childhood.

Fayuvi utilizes an adeno-associated viral vector to deliver a functional copy of the human SGSH gene directly into cells, restoring the missing enzyme responsible for clearing heparan sulfate accumulations. Clinical trial data submitted to the FDA showed sustained enzyme expression and a stabilization of cognitive decline markers when administered early. The therapeutic model underscores the divide between managing long-term symptoms and correcting foundational molecular errors.

For parents and clinicians navigating complex pediatric diagnoses, the approval reinforces the necessity of early whole-exome sequencing when unexplained developmental delays appear. Treat your child's raw diagnostic data as an actionable baseline, and ensure you retain full personal ownership of genomic files as new targeted therapies clear regulatory review.